BOSTON SCIENTIFIC CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BSX in the last 30 days.
See all $BSX insider activity →Evercore ISI reduced its price target for Boston Scientific from $65 to $52. The company also announced management changes effective January 1, 2027. Boston Scientific's stock is currently trading at $42.16, down 3.44% year-to-date.
Boston Scientific will reorganize into three segments: Interventional Therapies, Rhythm Solutions, and MedSurg, effective January 1, 2027. The move aims to streamline decision-making and investment allocation. Interventional Therapies will cover cardiology, vascular, and oncology; Rhythm Solutions will include electrophysiology and cardiac rhythm management; MedSurg will encompass endoscopy, urology, and neuromodulation.
Boston Scientific appointed Joseph Fitzgerald as its new Chief Operating Officer. Separately, Citigroup lowered its price target on the company to $48 from $50, maintaining a neutral rating. The stock closed at $42.19, down 0.50%.
Over the past 7 days, AlphAI's AI scored 20 news stories mentioning BSX (BOSTON SCIENTIFIC CORP). Coverage has skewed bearish: 2 bullish, 12 neutral, and 6 bearish.
Recent BSX coverage spans financial news, regulation and corporate actions.
Analyst target cut suggests downward pressure on the stock.
The restructuring provides clearer segment visibility, which may modestly improve analyst coverage and investor confidence.
The appointment may be viewed as a positive leadership signal, potentially supporting the stock.
Potential short‑term pressure on BSX as analysts downgrade outlook.
The Underweight rating and target suggest potential downside pressure on BSX.
AlphAI scores every news story that mentions BSX with an AI model for sentiment and relevance, and aggregates insider trades from BOSTON SCIENTIFIC CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Evercore ISI reduced its price target for Boston Scientific from $65 to $52. The company also announced management changes effective January 1, 2027. Boston Scientific's stock is currently trading at $42.16, down 3.44% year-to-date.
1 min readBoston Scientific will reorganize into three segments: Interventional Therapies, Rhythm Solutions, and MedSurg, effective January 1, 2027. The move aims to streamline decision-making and investment allocation. Interventional Therapies will cover cardiology, vascular, and oncology; Rhythm Solutions will include electrophysiology and cardiac rhythm management; MedSurg will encompass endoscopy, urology, and neuromodulation.
1 min readBoston Scientific appointed Joseph Fitzgerald as its new Chief Operating Officer. Separately, Citigroup lowered its price target on the company to $48 from $50, maintaining a neutral rating. The stock closed at $42.19, down 0.50%.
1 min readBoston Scientific (BSX) shares fell after analysts initiated coverage with neutral to underweight ratings and lowered price targets. Citi cited potential fallout from a recent cyberattack. Despite steady revenue gains, weakness in key areas and higher debt may limit growth.
1 min readBarclays initiated coverage of Boston Scientific (BSX) with an Underweight rating and $165 price target. The firm sees opportunities in high-quality medical device stocks but expects sector fundamentals to stabilize in 2027. Barclays' top picks include Edwards Lifesciences, Stryker, Beta Bionics, DexCom, and LivaNova.
1 min readA Singapore court denied Boston Scientific's request to block a former director from joining Johnson & Johnson, rejecting its claim that the executive's relationships with key opinion leaders were trade connections worth protecting. The court found insufficient evidence linking these relationships to product sales or justifying a 12-month non-compete period. Boston Scientific and J&J compete in the medical technology space, particularly in electrophysiology.
2 min readBernstein lowered Boston Scientific's (BSX) price target to $54 from $60, citing competition from Abbott's (ABT) Amulet 360 device. BSX trades near its 52-week low at $42.60, down 55% YTD. Bernstein expects Amulet 360 to gain market share from BSX's Watchman product. InvestingPro data shows 10 analysts have revised BSX earnings downwards, but the stock has a low PEG ratio of 0.36. BSX also faces cyberattack fallout, with Wells Fargo estimating $300M in Q3 sales reduction.
2 min readCitigroup lowered its price target on Boston Scientific from $50 to $48, maintaining a neutral rating. The stock is trading at $42.60, down 1.46% in pre-market. The adjustment is based on valuation and earnings revisions.
1 min readRBC Capital analyst Kendall Au maintained a Buy rating on Boston Scientific (BSX) with a $70.00 price target. The stock closed at $43.23. The Street's consensus is Strong Buy, with a $58.58 average target, implying 35.51% upside. Boston Scientific reported Q2 revenue of $5.44B and net profit of $907M, up from $5.06B and $793M last year. Insider sentiment is positive, with recent purchases by directors.
1 min readFDA cleared Boston Scientific's SpaceOAR Flex Hydrogel, a rectal spacer for prostate cancer radiation therapy. The company claims it offers simpler setup and flexible delivery. Interim trial data showed 92.4% of patients had a 25% reduction in rectal radiation dose. Boston Scientific funded the study.
2 min read
